NO944924L - Fremgangsmåter for inhibering av Turner's syndrom - Google Patents
Fremgangsmåter for inhibering av Turner's syndromInfo
- Publication number
- NO944924L NO944924L NO944924A NO944924A NO944924L NO 944924 L NO944924 L NO 944924L NO 944924 A NO944924 A NO 944924A NO 944924 A NO944924 A NO 944924A NO 944924 L NO944924 L NO 944924L
- Authority
- NO
- Norway
- Prior art keywords
- syndrome
- procedures
- turner
- inhibiting
- inhibiting turner
- Prior art date
Links
- 208000026928 Turner syndrome Diseases 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/171,328 US5441966A (en) | 1993-12-21 | 1993-12-21 | Methods of inhibiting Turner's syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO944924D0 NO944924D0 (no) | 1994-12-19 |
| NO944924L true NO944924L (no) | 1995-06-22 |
Family
ID=22623350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO944924A NO944924L (no) | 1993-12-21 | 1994-12-19 | Fremgangsmåter for inhibering av Turner's syndrom |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5441966A (cs) |
| EP (1) | EP0659422A1 (cs) |
| JP (1) | JPH07223948A (cs) |
| KR (1) | KR950016735A (cs) |
| CN (1) | CN1108103A (cs) |
| AU (1) | AU8155394A (cs) |
| CA (1) | CA2138494A1 (cs) |
| CZ (1) | CZ322194A3 (cs) |
| HU (1) | HUT71337A (cs) |
| IL (1) | IL112053A0 (cs) |
| NO (1) | NO944924L (cs) |
| RU (1) | RU94045271A (cs) |
| ZA (1) | ZA9410098B (cs) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5847007A (en) | 1993-05-13 | 1998-12-08 | Neorx Corporation | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
| US5494929A (en) * | 1995-01-12 | 1996-02-27 | Eli Lilly And Company | Methods of inhibiting growth hormone effects |
| US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US6117911A (en) | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| CN1250563C (zh) | 1999-05-04 | 2006-04-12 | 斯特拉坎有限公司 | 雄激素糖苷及其产生雄性征的活性 |
| US6613083B2 (en) | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| AU672182B2 (en) * | 1991-11-27 | 1996-09-26 | Novo Nordisk A/S | Piperidine derivatives and their use in treating psychosis |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
-
1993
- 1993-12-21 US US08/171,328 patent/US5441966A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 HU HU9403672A patent/HUT71337A/hu unknown
- 1994-12-19 NO NO944924A patent/NO944924L/no unknown
- 1994-12-19 EP EP94309480A patent/EP0659422A1/en not_active Withdrawn
- 1994-12-19 AU AU81553/94A patent/AU8155394A/en not_active Abandoned
- 1994-12-19 JP JP6314557A patent/JPH07223948A/ja active Pending
- 1994-12-19 KR KR1019940034926A patent/KR950016735A/ko not_active Withdrawn
- 1994-12-19 CA CA002138494A patent/CA2138494A1/en not_active Abandoned
- 1994-12-19 IL IL11205394A patent/IL112053A0/xx unknown
- 1994-12-19 RU RU94045271/14A patent/RU94045271A/ru unknown
- 1994-12-19 ZA ZA9410098A patent/ZA9410098B/xx unknown
- 1994-12-19 CZ CZ943221A patent/CZ322194A3/cs unknown
- 1994-12-19 CN CN94119738A patent/CN1108103A/zh active Pending
-
1995
- 1995-05-22 US US08/445,812 patent/US5698572A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5698572A (en) | 1997-12-16 |
| CN1108103A (zh) | 1995-09-13 |
| JPH07223948A (ja) | 1995-08-22 |
| US5441966A (en) | 1995-08-15 |
| CA2138494A1 (en) | 1995-06-22 |
| IL112053A0 (en) | 1995-03-15 |
| HU9403672D0 (en) | 1995-02-28 |
| ZA9410098B (en) | 1996-06-19 |
| AU8155394A (en) | 1995-06-29 |
| RU94045271A (ru) | 1996-10-10 |
| EP0659422A1 (en) | 1995-06-28 |
| NO944924D0 (no) | 1994-12-19 |
| HUT71337A (en) | 1995-11-28 |
| CZ322194A3 (en) | 1995-08-16 |
| KR950016735A (ko) | 1995-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO944911L (no) | Ikke-peptid-takykininreseptorantagonister | |
| DK0652005T3 (da) | Fremgangsmåder til inhibering af endometriose | |
| NO944927L (no) | Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom | |
| MY132056A (en) | Methods of inhibiting physiological conditions associated with an excess of neuropeptide y. | |
| NO944919L (no) | Fremgangsmåte for å inhibere atrofi av huden eller vagina | |
| DK0664126T3 (da) | Hæmning af trombin | |
| NO944924L (no) | Fremgangsmåter for inhibering av Turner's syndrom | |
| NO973635L (no) | Fremgangsmåte for hemming av celle-celle adhesjon | |
| NO944914L (no) | Fremgangsmåte for å inhibere autoimmunsykdommer | |
| DK0651999T3 (da) | Fremgangsmåder til inhibering af livmoderfibrose | |
| NO944934L (no) | Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom | |
| DK0659417T3 (da) | Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen | |
| MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
| ZA956986B (en) | Methods of inhibiting viral replication. | |
| NO944926L (no) | Fremgangsmåter for å inhibere myeloperoksidaseaktivitet | |
| DK0652002T3 (da) | Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning | |
| NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
| DK0662325T3 (da) | Inhibering af ovariedysgenese, forsinket pubertet eller sexuel infantilisme | |
| NO944931L (no) | Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet | |
| NO970786L (no) | Fremgangsmåte for hemming av benprotesedegradering | |
| NO975580L (no) | Fremgangsmåte for å inhibere melanom | |
| NO944923L (no) | Hemming av vektökning eller indusering av vekttap | |
| NO973609L (no) | Fremgangsmåte for å inhibere effektene av IL-6 | |
| NO981578L (no) | FremgangsmÕte for hemming av plasminogenaktivatorhemmer I | |
| NO973103L (no) | Fremgangsmåte for inhibering av veksthormoneffekter |